Speedel Begins Pivotal Trial Of SPP301 In Diabetic Nephropathy July 13, 2005 By Jennifer Boggs Four months after reporting positive results from a Phase IIb trial of its endothelin A receptor antagonist, SPP301, in diabetic nephropathy, Speedel Group AG initiated a pivotal Phase III study in Type II diabetes patients. (BioWorld International)Read More